Showing results (61-70 of 81) with videos related to
Sort By:
Pageof 9
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 31, 2014
Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinomaElaine T Lam, Michael K K Wong, Neeraj Agarwal, et al.Journal of the American Academy of Dermatology|May 19, 2015
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCCAleksandar Sekulic, Michael R Migden, Karl Lewis, et al.The American Journal of Clinical Nutrition|January 5, 2002
Elevated plasma 4-pyridoxic acid in renal insufficiencyStephen P Coburn, Robert D Reynolds, J Dennis Mahuren, et al.The Lancet. Oncology|July 20, 2014
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b studyAntoni Ribas, Rene Gonzalez, Anna Pavlick, et al.Lancet (London, England)|June 15, 2020
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialRalf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanomaKazuo Koyanagi, Steven J O'Day, Peter Boasberg, et al.Journal of Translational Medicine|November 23, 2012
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusionAntoni Ribas, Jason A Chesney, Michael S Gordon, et al.The Lancet. Oncology|December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyPaolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study GroupDavid F McDermott, Jeffrey A Sosman, Rene Gonzalez, et al.Neuro-Oncology Advances|May 10, 2024
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasisAlexander M Menzies, Georgina V Long, Amiee Kohn, et al.Pageof 9